TOBAM’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.82M Sell
4,850
-1,840
-28% -$1.88M 1.41% 23
2026
Q1
$6.15M Buy
6,690
+902
+16% +$914K 1.6% 17
2025
Q4
$6.22M Buy
5,788
+2,755
+91% +$2.63M 1.53% 20
2025
Q3
$2.31M Sell
3,033
-373
-11% -$278K 0.84% 46
2025
Q2
$2.65M Sell
3,406
-1,645
-33% -$1.28M 1.04% 39
2025
Q1
$4.17M Sell
5,051
-3,421
-40% -$2.85M 1.78% 15
2024
Q4
$6.54M Sell
8,472
-6,312
-43% -$5.23M 2% 11
2024
Q3
$13.1M Sell
14,784
-7,388
-33% -$6.64M 2.39% 6
2024
Q2
$20.1M Sell
22,172
-21,432
-49% -$17.1M 3.15% 1
2024
Q1
$33.9M Sell
43,604
-13,302
-23% -$9.47M 3.04% 1
2023
Q4
$33.2M Sell
56,906
-1,635
-3% -$954K 2.9% 3
2023
Q3
$31.4M Buy
58,541
+18,294
+45% +$9.43M 2.52% 12
2023
Q2
$18.9M Sell
40,247
-24,839
-38% -$10.4M 1.42% 30
2023
Q1
$22.4M Sell
65,086
-18,359
-22% -$6.19M 1.47% 29
2022
Q4
$30.5M Sell
83,445
-8,654
-9% -$3.07M 2.02% 15
2022
Q3
$29.8M Sell
92,099
-18,551
-17% -$5.88M 2.08% 16
2022
Q2
$35.9M Sell
110,650
-73,636
-40% -$22.1M 2.25% 13
2022
Q1
$52.8M Sell
184,286
-24,715
-12% -$6.36M 2.65% 3
2021
Q4
$57.7M Sell
209,001
-27,467
-12% -$6.96M 2.6% 3
2021
Q3
$54.6M Buy
236,468
+19,116
+9% +$4.72M 2.32% 6
2021
Q2
$49.9M Buy
217,352
+114,334
+111% +$23M 2% 13
2021
Q1
$19.2M Buy
103,018
+99,981
+3,292% +$19.6M 0.82% 52
2020
Q4
$513K Buy
3,037
+141
+5% +$21.1K 0.02% 143
2020
Q3
$429K Buy
+2,896
New +$448K 0.02% 139
2019
Q3
Sell
-7,053
Closed -$781K 129
2019
Q2
$781K Buy
7,053
+961
+16% +$113K 0.04% 90
2019
Q1
$790K Sell
6,092
-10,651
-64% -$1.3M 0.04% 110
2018
Q4
$1.94M Buy
+16,743
New +$1.87M 0.09% 102
2018
Q2
Sell
-32,945
Closed -$2.55M 154
2018
Q1
$2.55M Buy
32,945
+1,280
+4% +$103K 0.1% 116
2017
Q4
$2.67M Buy
31,665
+3,363
+12% +$286K 0.12% 107
2017
Q3
$2.42M Buy
28,302
+10,554
+59% +$866K 0.09% 108
2017
Q2
$1.46M Buy
+17,748
New +$1.45M 0.05% 117

Other funds holding LLY

TOBAM's LLY Position: Q2 2026 in Review

TOBAM reduced its Eli Lilly (LLY) stake by 28% in Q2 2026, selling an estimated $1.88M and leaving 4,850 shares worth $5.82M. The position accounts for 1.41% of the portfolio, ranked #23.

TOBAM first reported a position in LLY in Q2 2017 and has held it in 31 quarters since. The position peaked at $57.7M in Q4 2021. 4,602 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • TOBAM held 4,850 shares of Eli Lilly worth $5.82M as of Q2 2026.
  • TOBAM sold 1,840 Eli Lilly shares in Q2 2026, an estimated $1.88M.
  • Eli Lilly made up 1.41% of TOBAM's portfolio in Q2 2026, its #23 holding.
  • TOBAM first reported a position in Eli Lilly in Q2 2017 and has held it in 31 quarters since.
  • TOBAM's Eli Lilly position peaked at $57.7M in Q4 2021.
  • 4,602 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on TOBAM's 13F filing for Q2 2026, filed 31 Jul 2026.